BIOHAVEN LTD (BHVN) Stock Price, Quote, News and Overview
NYSE:BHVN - New York Stock Exchange, Inc. - VGG1110E1079 - Common Stock - Currency: USD
BHVN Quote, Performance and Key Statistics
BIOHAVEN LTD
NYSE:BHVN (2/4/2025, 8:04:00 PM)
After market: 37.79 -1.52 (-3.87%)39.31
+1.6 (+4.24%)
The current stock price of BHVN is 39.31 USD. In the past month the price increased by 1.73%. In the past year, price decreased by -19.03%.
BHVN Latest News, Press Releases and Analysis
Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force
The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory framework for crypto assets.
What's Going On With Merus Stock Monday?
Merus announced a research collaboration and license agreement with Biohaven.
Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation
Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas. Announces multiple advancements across the...
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 43rd Annual J.P....
BHVN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 15.04 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About BHVN
Company Profile
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 239 full-time employees. The company went IPO on 2022-09-23. The firm is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
Company Info
BIOHAVEN LTD
215 Church Street
New Haven CONNECTICUT 06510 US
CEO: Vlad Coric
Employees: 239
Company Website: https://www.biohaven.com/
Investor Relations: https://ir.biohaven.com/
Phone: 12034040410
BHVN FAQ
What is the stock price of BHVN?
The current stock price of BHVN is 39.31 USD.
What is the symbol for BIOHAVEN LTD stock?
The exchange symbol of BIOHAVEN LTD is BHVN and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is BHVN stock listed?
BHVN stock is listed on the New York Stock Exchange, Inc. exchange.
Is BHVN a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for BHVN, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of BHVN.
Does BHVN stock pay dividends?
BHVN does not pay a dividend.
What is the Price/Earnings (PE) ratio of BHVN?
BHVN does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.35).
What is the Short Interest ratio of BHVN stock?
The outstanding short interest for BHVN is 11.64% of its float.
BHVN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BHVN. When comparing the yearly performance of all stocks, BHVN is a bad performer in the overall market: 87.6% of all stocks are doing better.
BHVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BHVN. While BHVN has a great health rating, there are worries on its profitability.
BHVN Financial Highlights
Over the last trailing twelve months BHVN reported a non-GAAP Earnings per Share(EPS) of -9.35. The EPS increased by -30.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -157.55% | ||
| ROE | -254.53% | ||
| Debt/Equity | 0 |
BHVN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to BHVN. The Buy consensus is the average rating of analysts ratings from 21 analysts.